IDStewardship

MARCH 7, 2025

In this article a clinical infectious diseases pharmacist reviews five things for pharmacists to know about measles in 2025. Here are five practical things for pharmacists to know about measles in 2025 First some basics Measles is also referred to as rubeola, 10-day measles, or red measles. Authored By: Timothy P. Gauthier, Pharm.D.,

Vaccines 299

Vaccines Immunization Communication Hospitals 299

NF2 BioSolutions

OCTOBER 4, 2024

I have enjoyed every moment, and I have made the most of all the opportunities to pass my way through the University of Manchester, NF2 research community and the Charity, all of whom have driven this research forward. Although VS and meningioma are both brain tumours in NF2, their immune cells act differently. So what have we found?

Immunization 105

Immunization Communication 105

PQA

DECEMBER 13, 2024

are wrapping up year four of Blueprint PQA 2025, PQAs five-year strategic plan. This two-year project will begin in early 2025. That work will continue in 2025. This fall, we launched a pilot to evaluate the effectiveness of pharmacies in improving adult immunization rates through VBAs with payers.

Communication 52

Communication Patient Care Immunization 52

European Pharmaceutical Review

DECEMBER 19, 2023

Available from: [link] Vaccines and Immunization. Immunization coverage. Since vaccines can now be reformulated to meet the relevant WHO guidelines, the route to a future of fridge-free vaccines is open. Internet] WHO. cited 2023July]. Internet] WHO. cited 2023July]. Available from: [link] WHO. Internet] WHO. cited 2023July].

Vaccines 111

Vaccines Communication Immunization Documentation 111

pharmaphorum

MARCH 9, 2021

1 Every year, 19,500 people are diagnosed with lymphoma 2 – a cancer affecting a certain type of white blood cell within the immune system – and can be classed as either slow or fast growing. This has also put the lymphoma community in the UK firmly on the global stage. Last accessed March 2021. Lymphoma Action. 2018, page 3.

Chemotherapy 52

Chemotherapy Communication Immunization 52

Pharmaceutical Technology

APRIL 20, 2023

The company’s patch technology delivers trace amounts of allergens to build an immune response. DBV expects to share topline data from the study in H1 2025. According to the company’s January 2023 corporate presentation, there are 280,000 toddlers and 390,000 children living with peanut allergy in the US.

FDA 52

FDA Communication Immunization 52

Pharmaceutical Technology

APRIL 24, 2023

. “Biologics products may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system. Please check your email to download the Whitepaper.

Vaccines 52

Vaccines Compounding Pharmaceutical Companies Pharmaceutical Companies 52